Epilepsy Foundation - New Therapy Commercialization Grants
Eligibility: The Epilepsy Foundation - New Therapy Commercialization Grants Program supports the development of more effective therapies by serving as a catalyst for moving innovative therapies from the laboratory to the patient. Investigators must hold a relevant advanced degree (M.D., and/or Ph.D.), and have completed all research training. This call for proposals is open to investigators at corporations as well as the academic/university arena.
Amount (USD): $100,000.00
Application Deadline: 3/1/14
Areas of Interest: Please refer to "Application Information" below
Duration (yrs): 2
Source: Epilepsy Foundation
Sponsor: Epilepsy Foundation
Application Information: Investigators must submit a Letter of Intent by March 7, 2014 by 11:59 pm ET. The deadline for receipt of full Grant proposals is April 21, 2014 by 11:59 pm ET. Applicants must demonstrate background work beyond the basic science discovery stage. Areas of interest include: Novel approaches to treatment; Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials; and Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).
Other: The mission of the New Therapy - Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups worldwide. The Program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program also encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source.